Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 15 May 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Net sales and operating income are expected to fall below the previous forecasts because sales after limited shipments did not grow as much as anticipated and the overseas competitive environment deteriorated in Sansho Pharmaceutical's New Applications business. Ordinary income is expected to exceed the previous forecast, mainly due to ¥5.3 billion in gains on valuation of derivatives and other factors, while net income attributable to owners of the parent is expected to fall below the previous forecast, mainly due to ¥14.7 billion in impairment loss on goodwill and other factors.
Impairment loss on goodwill: ¥14.7 billion (consolidated financial statements); valuation loss on shares of affiliates: ¥26.1 billion (extraordinary loss in the Company's non-consolidated financial statements)
| Item | Details |
|---|---|
| Net Sales | ¥280,000 million → ¥273,700 million（-2.3%） |
| Operating profit | ¥27,000 million → ¥23,100 million（-14.4%） |
| Ordinary income | ¥25,300 million → ¥28,000 million（+10.7%） |
| Profit attributable to owners of the parent | ¥17,700 million → ¥5,200 million（-70.6%） |
| Net income per share | 359.57 yen and sen → 105.63 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2025 |
| Previous-period results | Net sales: ¥259,594 million; operating income: ¥23,242 million; ordinary income: ¥26,152 million; net income attributable to owners of the parent: ¥18,986 million; net income per share: ¥385.71 (full year of the fiscal year ended March 2025) |
| Reason for the revision | Net sales and operating income are expected to fall below the previous forecasts because sales after limited shipments did not grow as much as anticipated and the overseas competitive environment deteriorated in Sansho Pharmaceutical's New Applications business. Ordinary income is expected to exceed the previous forecast, mainly due to ¥5.3 billion in gains on valuation of derivatives and other factors, while net income attributable to owners of the parent is expected to fall below the previous forecast, mainly due to ¥14.7 billion in impairment loss on goodwill and other factors. |
| Details and amount of extraordinary loss | Impairment loss on goodwill: ¥14.7 billion (consolidated financial statements); valuation loss on shares of affiliates: ¥26.1 billion (extraordinary loss in the Company's non-consolidated financial statements) |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales and operating income are expected to fall below forecasts because sales after limited shipments did not grow as much as anticipated and the overseas competitive environment deteriorated in Sansho Pharmaceutical's New Applications business. Ordinary income is expected to exceed the forecast, mainly due to ¥5.3 billion in gains on valuation of derivatives and other factors, while net income attributable to owners of the parent is expected to fall below the forecast, mainly due to ¥14.7 billion in impairment loss on goodwill and other factors.